The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment

Por Poon, Edmund, Mullins, Stefanie, Watkins, Amanda, Williams, Geoffrey S., Koopmann, Jens-Oliver, Di Genova, Gianfranco, Cumberbatch, Marie, Veldman-Jones, Margaret, Grosskurth, Shaun E., Sah, Vasu, Schuller, Alwin, Reimer, Corrine, Dovedi, Simon J., Smith, Paul D., Stewart, Ross, Wilkinson, Robert W.
Publicado no J Immunother Cancer (2017)

A Comprehensive Evaluation of Nasal and Bronchial Cytokines and Chemokines Following Experimental Rhinovirus Infection in Allergic Asthma: Increased Interferons (IFN-γ and IFN-λ) a...

Por Hansel, Trevor T., Tunstall, Tanushree, Trujillo-Torralbo, Maria-Belen, Shamji, Betty, del-Rosario, Ajerico, Dhariwal, Jaideep, Kirk, Paul D.W., Stumpf, Michael P.H., Koopmann, Jens, Telcian, Aurica, Aniscenko, Julia, Gogsadze, Leila, Bakhsoliani, Eteri, Stanciu, Luminita, Bartlett, Nathan, Edwards, Michael, Walton, Ross, Mallia, Patrick, Hunt, Toby M., Hunt, Trevor L., Hunt, Duncan G., Westwick, John, Edwards, Matthew, Kon, Onn Min, Jackson, David J., Johnston, Sebastian L.
Publicado no EBioMedicine (2017)